StrIVeMD Wellness and Ketamine
- PRP Therapy
- IV Therapy
- Ketamine Therapy
- Migraine Treatment
- Peptide Therapy
Dublin, OH
Ketamine Therapy clinics in Dublin
Dublin has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Ohio requires DEA registration and Ohio Medical Board compliance for ketamine; Spravato REMS is available through major health systems. Most Dublin clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Dublin only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Dublin, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Dublin sits in the premium range: single IV infusions run 600 to 1,000 dollars, a full 6 session protocol lands at 3,600 to 6,000, and Spravato copays depend on insurance coverage. A reputable Dublin ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Regulatory context
A note on Ohio's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Ohio Controlled Substances Act (ORC Chapter 3719)
Mirrors federal scheduling; no therapeutic access framework.
Ohio enforces federal scheduling. The State Medical Board of Ohio oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Ohio OARRS PDMP requires controlled substance reporting. Ohio has strict office-based anesthesia rules for procedures involving moderate or deep sedation.